Researchers at The Jackson Laboratory have created a panel of genetically diverse mice that accurately model the highly variable human response to SARS-CoV-2 infection.
FDA OKs First Interchangeable Biosimilars for Denosumab
The FDA approved injectable Jubbonti and Wyost as the first interchangeable biosimilars to denosumab (Prolia, Xgeva), and for all the same indications, including the prevention
March 7, 2024